{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:42:38Z","timestamp":1790026958471,"version":"4.0.1"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>For patients with high-risk cutaneous squamous cell carcinomas (cSCCs), current guidance suggests we should offer post-treatment follow-up appointments at regular intervals for 24 months. Is this to improve prognosis, provide psychological support or find the next cancer? Recent data confirm that recurrence and metastasis are rarer events, and that perhaps these intense follow-up schedules do not really lead to improved health outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To question whether current follow-up practices are truly needed by introducing an option of patient-initiated follow-up (PIFU).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We enrolled 476 patients with cSCC (January 2020\u2013January 2023) who fulfilled the definition of high-risk cSCC based on guidelines in use at the time. Of the total, 59 did not fulful the inclusion criteria and were excluded; 250 (52.5%) did not recontact us during the 2-year period, with no clinical record of complications or recurrences; and 167 (35.1%) utilized the PIFU pathway, of which 119 patients required only one face-to-face appointment. Seven patients (1.5%) developed metastatic disease, 11 (2.3%) developed recurrence and 68 (14.3%) developed cSCC at another site. All lesions were identified by the patient via PIFU. We saved 1250 follow-up appointments from those who did not contact us (n = 250), financially equating to \u00a3181 462.50.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our data imply that PIFU can be considered safe alternative practice for patients with cSCC. Patients independently identified the need for review without scheduled follow-up, making these appointments available to other patient cohorts. Although follow-up appointments may provide mental health support, they can be inconvenient and not the ideal use of our healthcare resources. Our findings support a call for revision of existing skin cancer health policies to cope with and subsequently improve our practices for better patient care.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae160","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T10:58:01Z","timestamp":1715770681000},"page":"1205-1212","source":"Crossref","is-referenced-by-count":2,"title":["Patient-initiated follow-up for high-risk cutaneous squamous cell carcinoma: how we do it and 2 years of\u00a0outcome data"],"prefix":"10.1093","volume":"49","author":[{"given":"Shafiah Muna","family":"Abdul Gafoor","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospitals Plymouth NHS Trust , Plymouth , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospitals Plymouth NHS Trust , Plymouth , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofya","family":"Diskantova","sequence":"additional","affiliation":[{"name":"University of Plymouth , Plymouth , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Woodcock","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospitals Plymouth NHS Trust , Plymouth , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0190-5023","authenticated-orcid":false,"given":"Sonam","family":"Yethenpa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Royal Cornwall Hospital, Royal Cornwall Hospitals NHS Trust , Truro , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Holloran","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospitals Plymouth NHS Trust , Plymouth , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospitals Plymouth NHS Trust , Plymouth , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"2024091818150385000_llae160-B1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/j.1365-2133.2003.05554.x","article-title":"Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer)","volume":"149","author":"Katalinic","year":"2003","journal-title":"Br J Dermatol"},{"key":"2024091818150385000_llae160-B2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3390\/cancers14020377","article-title":"The multidisciplinary management of cutaneous squamous cell carcinoma: a comprehensive review and clinical recommendations by a panel of experts","volume":"14","author":"Stanganelli","year":"2022","journal-title":"Cancers"},{"key":"2024091818150385000_llae160-B3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/cancers14030629","article-title":"Update on management recommendations for advanced cutaneous squamous cell carcinoma","volume":"14","author":"Garc\u00eda-Foncillas","year":"2022","journal-title":"Cancers"},{"key":"2024091818150385000_llae160-B4","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/bjd.15110","article-title":"Predicted cases of U.K. skin squamous cell carcinoma and basal cell carcinoma in 2020 and 2025: horizon planning for National Health Service \u00addermatology and dermatopathology","volume":"176","author":"Goon","year":"2017","journal-title":"Br J Dermatol"},{"key":"2024091818150385000_llae160-B5","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bjd.17873","article-title":"Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K. 2013\u201315: a cohort study","volume":"181","author":"Venables","year":"2019","journal-title":"Br J Dermatol"},{"key":"2024091818150385000_llae160-B6","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.ejca.2013.03.010","article-title":"Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis","volume":"49","author":"Flohil","year":"2013","journal-title":"Eur J Cancer"},{"key":"2024091818150385000_llae160-B7","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.ejca.2015.06.110","article-title":"Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline","volume":"51","author":"Stratigos","year":"2015","journal-title":"Eur J Cancer"},{"key":"2024091818150385000_llae160-B8","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaad.2017.10.007","article-title":"Guidelines of care for the management of cutaneous squamous cell carcinoma","volume":"78","author":"Group","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"2024091818150385000_llae160-B9","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.6004\/jnccn.2021.0059","article-title":"NCCN Guidelines\u00ae Insights: Squamous Cell Skin Cancer, Version 1.2022","volume":"19","author":"Schmults","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2024091818150385000_llae160-B10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaad.2022.02.056","article-title":"Risk factors for metastatic cutaneous squamous cell carcinoma: refinement and replication based on 2 nationwide nested case\u2013control studies","volume":"87","author":"Tokez","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2024091818150385000_llae160-B11","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/jso.23155","article-title":"The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors","volume":"106","author":"Brougham","year":"2012","journal-title":"J Surg Oncol"},{"key":"2024091818150385000_llae160-B12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bjd.19621","article-title":"British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020","volume":"184","author":"Keohane","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024091818150385000_llae160-B13","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/bjd\/ljad241","article-title":"Time to reconsider skin cancer-related follow-up visits","volume":"189","author":"Smak Gregoor","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024091818150385000_llae160-B14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7861\/futurehosp.4-2-121","article-title":"Promoting innovation in healthcare","volume":"4","author":"Kelly","year":"2017","journal-title":"Future Healthc J"},{"key":"2024091818150385000_llae160-B15","article-title":"Five Year Forward View","author":"NHS England","year":"2014"},{"key":"2024091818150385000_llae160-B16","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1038\/bjc.2011.419","article-title":"Recovery and self-management support following primary cancer treatment","volume":"105","author":"Foster","year":"2011","journal-title":"Br J Cancer"},{"key":"2024091818150385000_llae160-B17","doi-asserted-by":"crossref","first-page":"102183","DOI":"10.1016\/j.ejon.2022.102183","article-title":"Optimising patient-initiated follow-up care \u2013 a qualitative analysis of women with breast cancer in the UK","volume":"60","author":"Moore","year":"2022","journal-title":"Eur J Oncol Nurs"},{"key":"2024091818150385000_llae160-B18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s41927-020-00143-6","article-title":"Patient-Initiated Follow-Up (PIFU) as reorganized support for increased patient involvement \u2013 focus group discussions among patients\u2019 with inflammatory arthritis","volume":"4","author":"Bech","year":"2020","journal-title":"BMC Rheumatol"},{"key":"2024091818150385000_llae160-B19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejogrb.2022.02.181","article-title":"Patient initiated follow up in Obstetrics and Gynaecology: a systematic review","volume":"272","author":"Kershaw","year":"2022","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2024091818150385000_llae160-B20","article-title":"Implementing patient-initiated follow-up. Guidance for local health and care systems","author":"NHS England"},{"issue":"(Suppl. 7)","key":"2024091818150385000_llae160-B21","doi-asserted-by":"crossref","first-page":"znad258.535","DOI":"10.1093\/bjs\/znad258.535","article-title":"Introducing a Patient-Initiated Follow Up (PIFU) pathway to a district general hospital\u2019s urology department: a two-cycle quality improvement project following the first 100 patients","volume":"110","author":"Hirniak","year":"2023","journal-title":"Br J Surg"},{"key":"2024091818150385000_llae160-B22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ced\/llac037","article-title":"Patient-initiated follow-up in an Irish dermatology department: a pilot study","volume":"48","author":"Wolinska","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"2024091818150385000_llae160-B23","article-title":"Implementing patient initiated follow-up (PIFU) in dermatology services","author":"NHS England"},{"key":"2024091818150385000_llae160-B24","doi-asserted-by":"crossref","first-page":"954854","DOI":"10.3389\/fonc.2022.954854","article-title":"Patient initiated follow-up in \u00adcancer patients: a systematic review","volume":"12","author":"Newton","year":"2022","journal-title":"Front Oncol"},{"key":"2024091818150385000_llae160-B25","author":"British Association of Dermatologists. Clinical Services Unit"},{"issue":"S1","key":"2024091818150385000_llae160-B26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bjd.21452","article-title":"DS09: Targeted follow-up for cutaneous squamous cell carcinoma","volume":"187","author":"King","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024091818150385000_llae160-B27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.0007-0963.2001.04615.x","article-title":"Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma","volume":"146","author":"Motley","year":"2002","journal-title":"Br J Dermatol"},{"key":"2024091818150385000_llae160-B28","doi-asserted-by":"crossref","first-page":"113251","DOI":"10.1016\/j.ejca.2023.113251","article-title":"European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention \u2013 Update 2023","volume":"193","author":"Stratigos","year":"2023","journal-title":"Eur J Cancer"},{"key":"2024091818150385000_llae160-B29","author":"British Association of Dermatologists"},{"key":"2024091818150385000_llae160-B30","article-title":"Living with and beyond cancer: taking action to improve outcomes","author":"National Cancer Survivorship Initiative"},{"key":"2024091818150385000_llae160-B31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1471-2407-11-279","article-title":"Underuse of long-term routine hospital follow-up care in patients with a history of breast cancer?","volume":"11","author":"Lu","year":"2011","journal-title":"BMC Cancer"},{"key":"2024091818150385000_llae160-B32","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1080\/110241501316914849","article-title":"Periodic follow-up after breast cancer and the effect on survival","volume":"167","author":"te Boekhorst","year":"2001","journal-title":"Eur J Surg"},{"key":"2024091818150385000_llae160-B33","first-page":"A4855","article-title":"Current organisation of follow-up does not meet cancer patients\u2019 needs","volume":"61","author":"Sperling","year":"2014","journal-title":"Dan Med J"},{"key":"2024091818150385000_llae160-B34","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/sj.bjc.6605638","article-title":"Patient satisfaction with GP-led melanoma follow-up: a randomised controlled trial","volume":"102","author":"Murchie","year":"2010","journal-title":"Br J Cancer"},{"key":"2024091818150385000_llae160-B35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/1471-0528.14000","article-title":"Comparing hospital and telephone follow-up for patients treated for stage-I endometrial cancer (ENDCAT trial): a randomised, multicentre, non-inferiority trial","volume":"124","author":"Beaver","year":"2017","journal-title":"BJOG"},{"key":"2024091818150385000_llae160-B36","author":"National Institute for Health and Care Excellence (NICE)"},{"key":"2024091818150385000_llae160-B37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejogrb.2020.03.028","article-title":"Patient initiated follow up after gynaecological malignancy: national survey of current UK practice","volume":"248","author":"Coleman","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2024091818150385000_llae160-B38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.2011.535","article-title":"Personalised cancer follow-up: risk stratification, needs assessment or both?","volume":"106","author":"Watson","year":"2012","journal-title":"Br J Cancer"},{"key":"2024091818150385000_llae160-B39","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/1471-0528.15396","article-title":"Patient-initiated follow up affects fear of recurrence and healthcare use: a randomised trial in early-stage endometrial cancer","volume":"125","author":"Jeppesen","year":"2018","journal-title":"BJOG"},{"key":"2024091818150385000_llae160-B40","doi-asserted-by":"crossref","first-page":"e12577","DOI":"10.1111\/ecc.12577","article-title":"Open access follow-up care for early breast cancer: a randomised controlled quality of life analysis","volume":"26","author":"Kirshbaum","year":"2016","journal-title":"Eur J Cancer Care"},{"key":"2024091818150385000_llae160-B41","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00520-017-3595-x","article-title":"Follow-up after curative treatment for colorectal cancer: longitudinal evaluation of patient initiated follow-up in the first 12 months","volume":"25","author":"Batehup","year":"2017","journal-title":"Support Care Cancer"},{"key":"2024091818150385000_llae160-B42","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-84702-9","volume-title":"Handbook of Quality of Life in Cancer","author":"Kassianos","year":"2022"},{"key":"2024091818150385000_llae160-B43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejon.2003.12.005","article-title":"Nurse-led follow-up on demand or by a physician after breast cancer surgery: a randomised study","volume":"8","author":"Koinberg","year":"2004","journal-title":"Eur J Oncol Nurs"},{"key":"2024091818150385000_llae160-B44","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/pon.576","article-title":"Patient initiated follow up of breast cancer","volume":"11","author":"Brown","year":"2002","journal-title":"Psychooncology"},{"key":"2024091818150385000_llae160-B45","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/BF02054122","article-title":"Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up","volume":"38","author":"Ohlsson","year":"1995","journal-title":"Dis Colon Rectum"},{"key":"2024091818150385000_llae160-B46","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejon.2008.11.005","article-title":"Breast cancer follow up: a randomised controlled trial comparing point of need access versus routine 6-monthly clinical review","volume":"13","author":"Sheppard","year":"2009","journal-title":"Eur J Oncol Nurs"},{"key":"2024091818150385000_llae160-B47","doi-asserted-by":"crossref","first-page":"e12997","DOI":"10.1111\/ecc.12997","article-title":"Acceptability and utilisation of patient-initiated follow-up for endometrial cancer amongst women from diverse ethnic and social backgrounds: a mixed methods study","volume":"28","author":"Kumarakulasingam","year":"2019","journal-title":"Eur J Cancer Care (Engl"},{"key":"2024091818150385000_llae160-B48","doi-asserted-by":"crossref","first-page":"101704","DOI":"10.1016\/j.ejon.2019.101704","article-title":"Exploring the acceptability and feasibility of patient-initiated follow-up for women treated for stage I endometrial cancer","volume":"44","author":"Beaver","year":"2020","journal-title":"Eur J Oncol Nurs"},{"key":"2024091818150385000_llae160-B49","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/jamadermatol.2013.2139","article-title":"Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study","volume":"149","author":"Schmults","year":"2013","journal-title":"JAMA Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae160\/58379042\/llae160.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/10\/1205\/59183720\/llae160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/10\/1205\/59183720\/llae160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T18:15:14Z","timestamp":1726683314000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/10\/1205\/7673541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5,15]]},"published-print":{"date-parts":[[2024,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae160","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,5,15]]}}}